AEON Biopharma
AEON
15 hedge funds and large institutions have $29.3M invested in AEON Biopharma in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 16 closing their positions.
144% more capital invested
Capital invested by funds: $12M → $29.3M (+$17.2M)
8.84% more ownership
Funds ownership: 4.8% → 13.63% (+8.8%)
12% less funds holding
Funds holding: 17 → 15 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Atalaya Capital Management
New York
|
+$23.4M |
| 2 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$2M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.64M |
| 4 |
BlackRock
New York
|
+$1.54M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
-$2.49M |
| 2 |
FTCM
Fir Tree Capital Management
New York
|
-$2M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$1.58M |
| 4 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$1.42M |
| 5 |
TCM
Tenor Capital Management
New York
|
-$1.42M |
AEON Hedge Fund Activity: Q3 2023 in Review
15 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q3 2023, worth a combined $29.3M — up 144% from $12M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AEON and 14 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Atalaya Capital Management, opening a new position worth an estimated $23.4M. The largest seller was Saba Capital Management, exiting entirely with an estimated $2.49M sold.
- 15 institutional investors held AEON Biopharma (AEON) as of Q3 2023, down from 17 in Q2 2023.
- Funds reported $29.3M of AEON Biopharma stock for Q3 2023, up 144% quarter-over-quarter.
- 14 funds opened new AEON Biopharma positions in Q3 2023 and 16 closed out, a net change of -2 holders.
- The largest AEON Biopharma buyer in Q3 2023 was Atalaya Capital Management, an estimated $23.4M added.
- The largest AEON Biopharma seller in Q3 2023 was Saba Capital Management, an estimated $2.49M sold.
Based on aggregated 13F filings for Q3 2023.